Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Dec;16(6):663–668. doi: 10.1111/j.1365-2125.1983.tb02238.x

Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.

A Markel, J G Brook, Y Levy, M Aviram, M B Youdim
PMCID: PMC1428341  PMID: 6661351

Abstract

Fourteen patients with established hypertension followed a double-blind crossover-styled trial to study the effects of 100 mg/day atenolol compared to placebo. Atenolol was found to be an effective antihypertensive agent, reducing both systolic and diastolic blood pressure. Hypertensive patients appear to have increased in vitro platelet adhesion and aggregation. Atenolol significantly reduced platelet adhesion, but had little effect on aggregation. This may be important in contributing towards the now-recognised cardio-protective effect of the beta-adrenoceptor blocking agents. Blood chemistry and haematological parameters were unchanged; but whereas plasma cholesterol and plasma triglyceride levels remained normal, there was a significant fall in plasma high-density lipoprotein cholesterol levels. Side effects were very few.

Full text

PDF
663

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aviram M., Brook G. J. The effect of human plasma on platelet function in familial hypercholesterolemia. Thromb Res. 1982 Apr 15;26(2):101–109. doi: 10.1016/0049-3848(82)90019-6. [DOI] [PubMed] [Google Scholar]
  2. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  3. Barrett A. M. The pharmacology of atenolol. Postgrad Med J. 1977;53 (Suppl 3):58–64. [PubMed] [Google Scholar]
  4. Berglund G., Andersson O., Larsson O., Wilhelmsen L. Antihypertensive effect and side-effects of bendroflumethiazide and propranolol. Acta Med Scand. 1976;199(6):499–506. doi: 10.1111/j.0954-6820.1976.tb06770.x. [DOI] [PubMed] [Google Scholar]
  5. Berglund G., Andersson O. beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects. Lancet. 1981 Apr 4;1(8223):744–747. doi: 10.1016/s0140-6736(81)92624-6. [DOI] [PubMed] [Google Scholar]
  6. Berglund G., Sannerstedt R., Andersson O., Wedel H., Wilhelmsen L., Hansson L., Sivertsson R., Wikstrand J. Coronary heart-disease after treatment of hypertension. Lancet. 1978 Jan 7;1(8054):1–5. doi: 10.1016/s0140-6736(78)90356-2. [DOI] [PubMed] [Google Scholar]
  7. Brook J. G., Aviram M., Viener A., Shilansky E., Markiewicz W. High-density lipoprotein subfractions in normolipidemic patients with coronary atherosclerosis. Circulation. 1982 Nov;66(5):923–926. doi: 10.1161/01.cir.66.5.923. [DOI] [PubMed] [Google Scholar]
  8. Conway J. Problems in the management of hypertension. Postgrad Med J. 1977;53 (Suppl 3):176–178. [PubMed] [Google Scholar]
  9. Day J. L., Metcalfe J., Simpson C. N. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J (Clin Res Ed) 1982 Apr 17;284(6323):1145–1148. doi: 10.1136/bmj.284.6323.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Day J. L., Simpson N., Metcalfe J., Page R. L. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J. 1979 Jan 13;1(6156):77–80. doi: 10.1136/bmj.1.6156.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frishman W. H., Christodoulou J., Weksler B., Smithen C., Killip T., Scheidt S. Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J. 1978 Feb;95(2):169–179. doi: 10.1016/0002-8703(78)90460-x. [DOI] [PubMed] [Google Scholar]
  12. Frishman W. H., Weksler B., Christodoulou J. P., Smithen C., Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation. 1974 Nov;50(5):887–896. doi: 10.1161/01.cir.50.5.887. [DOI] [PubMed] [Google Scholar]
  13. Helgeland A., Hjermann I., Leren P., Enger S., Holme I. High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J. 1978 Aug 5;2(6134):403–403. doi: 10.1136/bmj.2.6134.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Keber I., Jerse M., Keber D., Stegnar M. The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease. Br J Clin Pharmacol. 1979 Mar;7(3):287–291. doi: 10.1111/j.1365-2125.1979.tb00934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Knapp M. S. Effect of once-daily atenolol on ambulatory blood pressure. Br Med J. 1979 Feb 17;1(6161):490–491. doi: 10.1136/bmj.1.6161.490-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kwaan H. C., Colwell J. A., Cruz S., Suwanwela N., Dobbie J. G. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med. 1972 Aug;80(2):236–246. [PubMed] [Google Scholar]
  17. Lambert D. M. Effect of propranolol on mortality in patients with angina. Postgrad Med J. 1976;52 (Suppl 4):57–60. [PMC free article] [PubMed] [Google Scholar]
  18. Laragh J. H. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med. 1976 Nov;61(5):797–810. doi: 10.1016/0002-9343(76)90161-3. [DOI] [PubMed] [Google Scholar]
  19. Leon R., Tiarks C. Y., Pechet L. Some observations on the in vivo effect of propranolol on platelet aggregation and release. Am J Hematol. 1978;5(2):117–121. doi: 10.1002/ajh.2830050206. [DOI] [PubMed] [Google Scholar]
  20. Leren P., Foss P. O., Helgeland A., Hjermann I., Holme I., Lund-Larsen P. G. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet. 1980 Jul 5;2(8184):4–6. doi: 10.1016/s0140-6736(80)92888-3. [DOI] [PubMed] [Google Scholar]
  21. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  22. Mustard J. F., Packham M. A. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh. 1975 Jun 30;33(3):444–456. [PubMed] [Google Scholar]
  23. Nathan I., Dvilansky A., Sage J., Korczyn A. D. Effects of propranolol and pindolol on platelet aggregation and serotonin release. Life Sci. 1977 Feb 1;20(3):407–411. doi: 10.1016/0024-3205(77)90380-0. [DOI] [PubMed] [Google Scholar]
  24. Rapoport J., Aviram M., Chaimovitz C., Brook J. G. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med. 1978 Dec 14;299(24):1326–1329. doi: 10.1056/NEJM197812142992402. [DOI] [PubMed] [Google Scholar]
  25. Simpson W. T. Nature and incidence of unwanted effects with atenolol. Postgrad Med J. 1977;53 (Suppl 3):162–167. [PubMed] [Google Scholar]
  26. Sleight P., Floras J., Jones J. V., Hassan M. O. Effect of once-daily atenolol on ambulatory blood pressure. Br Med J. 1979 Feb 17;1(6161):491–491. doi: 10.1136/bmj.1.6161.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Small M., Douglas J. T., Aherne G. W., Orr M., Lowe G. D., Forbes C. D., Prentice C. R. Effects of the non-selective beta-adrenoceptor blocking agent, carteolol, on platelet function, blood coagulation and viscosity. Thromb Res. 1982 Feb 15;25(4):351–360. doi: 10.1016/0049-3848(82)90235-3. [DOI] [PubMed] [Google Scholar]
  28. Streja D., Mymin D. Effect of propranolol on HDL cholesterol concentrations. Br Med J. 1978 Nov 25;2(6150):1495–1495. doi: 10.1136/bmj.2.6150.1495-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tanaka N., Sakaguchi S., Oshige K., Niimura T., Kanehisa T. Effect of chronic administration of propranolol on lipoprotein composition. Metabolism. 1976 Oct;25(10):1071–1075. doi: 10.1016/0026-0495(76)90014-7. [DOI] [PubMed] [Google Scholar]
  30. Thaulow E., Kjekshus J., Erikssen J. Effect of timolol on platelet aggregation in coronary heart disease. Acta Med Scand Suppl. 1981;651:101–109. doi: 10.1111/j.0954-6820.1981.tb03640.x. [DOI] [PubMed] [Google Scholar]
  31. Trafford J. A., Horn C. R., O'Neal H., McGonigle R., Halford-Maw L., Evans R. Five year follow-up of effects of treatment of mild and moderate hypertension. Br Med J (Clin Res Ed) 1981 Apr 4;282(6270):1111–1113. doi: 10.1136/bmj.282.6270.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vlachakis N. D., Aledort L. Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol. 1980 Feb;45(2):321–325. doi: 10.1016/0002-9149(80)90653-0. [DOI] [PubMed] [Google Scholar]
  33. Weksler B. B., Gillick M., Pink J. Effect of propranolol on platelet function. Blood. 1977 Feb;49(2):185–196. [PubMed] [Google Scholar]
  34. Zacharias F. J., Cowen K. J., Cuthbertson P. F., Johnson T. B., Prestt J., Thompson J., Vickers J., Simpson W. T., Tuson R. Atenolol in hypertension a study of long-term therapy. Postgrad Med J. 1977;53 (Suppl 3):102–110. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES